The Board of Directors of Zhejiang Hisun Pharmaceutical Co., Ltd. has authorized a buyback plan on December 22, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.17 CNY | +0.99% |
|
+2.58% | -23.40% |
06-27 | Hisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation | MT |
06-27 | Hisun Pharmaceutical's Leukemia Drug Gets Marketing Approval | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.40% | 1.16B | |
+56.20% | 816B | |
+39.69% | 634B | |
-7.50% | 351B | |
+16.02% | 323B | |
+6.96% | 293B | |
+13.43% | 238B | |
+0.74% | 222B | |
+13.34% | 218B | |
+8.12% | 167B |
- Stock Market
- Equities
- 600267 Stock
- News Zhejiang Hisun Pharmaceutical Co., Ltd.
- Zhejiang Hisun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.